Literature DB >> 16226438

CD8+ T cells in autoimmunity.

Ulrich Walter1, Pere Santamaria.   

Abstract

Mounting evidence shows that CD8(+) T cells contribute to the initiation, progression and regulation of several pathogenic autoimmune responses in which these cells were not previously thought to play a major role. CD8(+) T cells can kill target cells directly, by recognizing peptide-MHC complexes on target cells, or indirectly, by secreting cytokines capable of signaling through death receptors expressed on the target cell surface. Autoreactive CD8(+) T cells can also contribute to autoimmunity by releasing cytokines capable of increasing the susceptibility of target cells to cytotoxicity, or by secreting chemokines that attract other immune cells to the site of autoimmunity. Autoreactive CD8(+) T cells can also downregulate autoimmune responses. Recent important advances include a mechanistic understanding of events leading to the activation and recruitment of autoreactive CD8(+) T cells in certain autoimmune responses and a greater appreciation of the diverse roles that these T cells play in autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226438     DOI: 10.1016/j.coi.2005.09.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  54 in total

1.  Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides.

Authors:  Katherina Siewert; Joachim Malotka; Naoto Kawakami; Hartmut Wekerle; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

Review 2.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

3.  Enhanced Direct Major Histocompatibility Complex Class I Self-Antigen Presentation Induced by Chlamydia Infection.

Authors:  Erik D Cram; Ryan S Simmons; Amy L Palmer; William H Hildebrand; Daniel D Rockey; Brian P Dolan
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

4.  Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells.

Authors:  Patrick Trépanier; Dominique Chabot; Renée Bazin
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

Review 5.  CD8(+) Tregs in autoimmunity: learning "self"-control from experience.

Authors:  Sue Tsai; Xavier Clemente-Casares; Pere Santamaria
Journal:  Cell Mol Life Sci       Date:  2011-06-14       Impact factor: 9.261

Review 6.  Targeted immune interventions for type 1 diabetes: not as easy as it looks!

Authors:  Mark R Rigby; Mario R Ehlers
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

7.  Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Authors:  Matthew B Dong; Guangchuan Wang; Ryan D Chow; Lupeng Ye; Lvyun Zhu; Xiaoyun Dai; Jonathan J Park; Hyunu R Kim; Youssef Errami; Christopher D Guzman; Xiaoyu Zhou; Krista Y Chen; Paul A Renauer; Yaying Du; Johanna Shen; Stanley Z Lam; Jingjia J Zhou; Donald R Lannin; Roy S Herbst; Sidi Chen
Journal:  Cell       Date:  2019-08-22       Impact factor: 41.582

8.  Selective phosphorylation of the Dlg1AB variant is critical for TCR-induced p38 activation and induction of proinflammatory cytokines in CD8+ T cells.

Authors:  Jillian Crocetti; Oscar Silva; Lisa A Humphries; Michelle D Tibbs; M Carrie Miceli
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

Review 9.  Alveolar epithelial and endothelial cell apoptosis in emphysema: what we know and what we need to know.

Authors:  Mathieu C Morissette; Julie Parent; Julie Milot
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15

10.  Identification of novel IGRP epitopes targeted in type 1 diabetes patients.

Authors:  Irene Jarchum; Lynn Nichol; Massimo Trucco; Pere Santamaria; Teresa P DiLorenzo
Journal:  Clin Immunol       Date:  2008-03-20       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.